Novasep Attracts Top Talent to Complete its Executive Team
News Jan 20, 2014
Novasep has announced that it has appointed Thierry van Nieuwenhove as president of the Synthesis Business Unit. Van Nieuwenhove’s arrival completes Novasep’s executive committee.
With its full executive committee (COMEX) now on board, Novasep achieves another key milestone in its strategic development.
Educated as a bio-engineer, Van Nieuwenhove, 40, holds a masters degree in chemistry and biochemistry from the Catholic University of Louvain, Belgium.
He joins Novasep from Ajinomoto-Omnichem, a European synthetic molecules custom manufacturing organization (CMO) owned by a top Japanese firm, where he held consecutive positions as director, then general manager and member of the board.
His skill set includes driving business unit growth, leading global teams including sales and business development, R&D, supply chain and purchasing, as well as mergers and acquisitions.
“We are thrilled to welcome Thierry to Novasep as president of the Synthesis Business Unit,” said Michel Spagnol, CEO of Novasep. “His broad experience in driving multicultural custom synthesis businesses will complement our COMEX skills perfectly. Thierry possesses the dynamics to boost Novasep’s CMO business in all our key markets.”
“I am very pleased to join Novasep,” said Thierry Van Nieuwenhove. “With its unique pool of specialized technologies and talents, Novasep is well positioned for growth as a top tier service provider for the life sciences industry. The group as a whole has tremendous opportunities to develop. Really innovative solutions can come out from the cross-fertilization of its several specialized technologies and application markets that will build future Novasep expertise. I am excited to be part of it.”
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE